ArticleFrontiers in microbiology2013
Hepatitis C virus infection and related liver disease: the quest for the best animal model.
Article in Frontiers in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A Role for B Cells to Transmit Hepatitis C Virus Infection.Frontiers in immunology · 2021Observational
- Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors.BMC medical genomics · 2019Article
- Hepatitis C Virus Infection and Vaccine Development.Journal of clinical and experimental hepatology · 2018Review
- Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection.World journal of hepatology · 2017Review
- Review
- Status of hepatitis C virus vaccination: Recent update.World journal of gastroenterology · 2016Review
- State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.Journal of immunology research · 2016Review
- Progress in the development of vaccines for hepatitis C virus infection.World journal of gastroenterology · 2015Review
- Review
- Animal models for the study of HCV.Current opinion in virology · 2015Review
- Proteomic approaches to analyzing hepatitis C virus biology.Proteomics · 2015Review
- Hepatitis C virus-induced hepatocellular carcinoma.Clinical and molecular hepatology · 2015Review
- Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents.World journal of hepatology · 2015Review
- Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.Journal of clinical and translational hepatology · 2015Review
- Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.Annual review of genetics · 2015Review
- Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Journal of hepatology · 2014Review
- A new HCV mouse model on the block.Cell research · 2014Article
- Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.Virus genes · 2014Article
- The past, present and future of neutralizing antibodies for hepatitis C virus.Antiviral research · 2014Review
- Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma (HCC) making the virus the most common cause of liver failure and transplantation. HCV is estimated to chronically affect 130 million individuals and to lead to more than 350,000 deaths per year worldwide. A vaccine is currently not available. The recently developed direct acting antivirals (DAAs) have markedly increased the efficacy of the standard of care but are not efficient enough to completely cure all chronically infected patients and their toxicity limits their use in patients with advanced liver disease, co-morbidity or transplant recipients. Because of the host restriction, which is limited to humans and non-human primates, in vivo study of HCV infection has been hampered since its discovery more than 20 years ago. The chimpanzee remains the most physiological model to study the innate and adaptive immune responses, but its use is ethically difficult and is now very restricted and regulated. The development of a small animal model that allows robust HCV infection has been achieved using chimeric liver immunodeficient mice, which are therefore not suitable for studying the adaptive immune responses. Nevertheless, these models allowed to go deeply in the comprehension of virus-host interactions and to assess different therapeutic approaches. The immunocompetent mouse models that were recently established by genetic humanization have shown an interesting improvement concerning the study of the immune responses but are still limited by the absence of the complete robust life cycle of the virus. In this review, we will focus on the relevant available animal models of HCV infection and their usefulness for deciphering the HCV life cycle and virus-induced liver disease, as well as for the development and evaluation of new therapeutics. We will also discuss the perspectives on future immunocompetent mouse models and the hurdles to their development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.